Oral secretory leukocyte protease inhibitor (SLPI): Associations with oropharyngeal cancer and treatment outcome.

<h4>Background</h4>Rates of oropharyngeal cancer (OPC) associated with alcohol & tobacco use have decreased, while human papillomavirus (HPV) associated OPC has increased among men in the US. Secretory leukocyte protease inhibitor (SLPI), detectable in a variety of secretions, has be...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Brittney L Dickey, Bradley Sirak, Laura Martin-Gomez, Richard R Reich, Martha Abrahamsen, Kimberly Isaacs-Soriano, Christine H Chung, Anna R Giuliano
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/ef3b1aeae8964c278ab48c2ed0cc7904
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ef3b1aeae8964c278ab48c2ed0cc7904
record_format	dspace
spelling	oai:doaj.org-article:ef3b1aeae8964c278ab48c2ed0cc79042021-12-02T20:15:38ZOral secretory leukocyte protease inhibitor (SLPI): Associations with oropharyngeal cancer and treatment outcome.1932-620310.1371/journal.pone.0254161https://doaj.org/article/ef3b1aeae8964c278ab48c2ed0cc79042021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0254161https://doaj.org/toc/1932-6203<h4>Background</h4>Rates of oropharyngeal cancer (OPC) associated with alcohol & tobacco use have decreased, while human papillomavirus (HPV) associated OPC has increased among men in the US. Secretory leukocyte protease inhibitor (SLPI), detectable in a variety of secretions, has been implicated in cancers of the head and neck, associated with tumor progression and anti-viral activity. Using the recently verified oral gargle specimen, this study aimed to assess the association of salivary SLPI expression with risk of OPC and response to treatment.<h4>Methods</h4>A case-control study design compared levels of salivary SLPI among OPC cases to age and tobacco smoking matched healthy controls. Oral HPV DNA and SLPI was quantified from oral gargle specimens. Logistic regression estimated odds ratios (OR) and 95% confidence intervals (CI) for associations of oral SLPI and risk of OPC and treatment outcomes.<h4>Results</h4>In crude and adjusted analyses of 96 OPC cases and 97 age- and smoking-matched controls, OPC was not significantly associated with oral gargle SLPI levels. Among cases, oral SLPI was associated with tonsillectomy (p = 0.018) and among controls oral SLPI was associated with HPV in the oral gargle (p = 0.008). Higher concentrations of SLPI was significantly associated with increased odds of incomplete treatment response (T2: OR: 12.39; 95% CI: 1.44-106.72; T3: OR: 9.86; 95% CI: 1.13-85.90) among all cases, but not among P16+ cases.<h4>Conclusions</h4>Salivary SLPI was not associated with OPC risk but was associated with higher odds of an incomplete treatment response.Brittney L DickeyBradley SirakLaura Martin-GomezRichard R ReichMartha AbrahamsenKimberly Isaacs-SorianoChristine H ChungAnna R GiulianoPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 7, p e0254161 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Brittney L Dickey Bradley Sirak Laura Martin-Gomez Richard R Reich Martha Abrahamsen Kimberly Isaacs-Soriano Christine H Chung Anna R Giuliano Oral secretory leukocyte protease inhibitor (SLPI): Associations with oropharyngeal cancer and treatment outcome.
description	<h4>Background</h4>Rates of oropharyngeal cancer (OPC) associated with alcohol & tobacco use have decreased, while human papillomavirus (HPV) associated OPC has increased among men in the US. Secretory leukocyte protease inhibitor (SLPI), detectable in a variety of secretions, has been implicated in cancers of the head and neck, associated with tumor progression and anti-viral activity. Using the recently verified oral gargle specimen, this study aimed to assess the association of salivary SLPI expression with risk of OPC and response to treatment.<h4>Methods</h4>A case-control study design compared levels of salivary SLPI among OPC cases to age and tobacco smoking matched healthy controls. Oral HPV DNA and SLPI was quantified from oral gargle specimens. Logistic regression estimated odds ratios (OR) and 95% confidence intervals (CI) for associations of oral SLPI and risk of OPC and treatment outcomes.<h4>Results</h4>In crude and adjusted analyses of 96 OPC cases and 97 age- and smoking-matched controls, OPC was not significantly associated with oral gargle SLPI levels. Among cases, oral SLPI was associated with tonsillectomy (p = 0.018) and among controls oral SLPI was associated with HPV in the oral gargle (p = 0.008). Higher concentrations of SLPI was significantly associated with increased odds of incomplete treatment response (T2: OR: 12.39; 95% CI: 1.44-106.72; T3: OR: 9.86; 95% CI: 1.13-85.90) among all cases, but not among P16+ cases.<h4>Conclusions</h4>Salivary SLPI was not associated with OPC risk but was associated with higher odds of an incomplete treatment response.
format	article
author	Brittney L Dickey Bradley Sirak Laura Martin-Gomez Richard R Reich Martha Abrahamsen Kimberly Isaacs-Soriano Christine H Chung Anna R Giuliano
author_facet	Brittney L Dickey Bradley Sirak Laura Martin-Gomez Richard R Reich Martha Abrahamsen Kimberly Isaacs-Soriano Christine H Chung Anna R Giuliano
author_sort	Brittney L Dickey
title	Oral secretory leukocyte protease inhibitor (SLPI): Associations with oropharyngeal cancer and treatment outcome.
title_short	Oral secretory leukocyte protease inhibitor (SLPI): Associations with oropharyngeal cancer and treatment outcome.
title_full	Oral secretory leukocyte protease inhibitor (SLPI): Associations with oropharyngeal cancer and treatment outcome.
title_fullStr	Oral secretory leukocyte protease inhibitor (SLPI): Associations with oropharyngeal cancer and treatment outcome.
title_full_unstemmed	Oral secretory leukocyte protease inhibitor (SLPI): Associations with oropharyngeal cancer and treatment outcome.
title_sort	oral secretory leukocyte protease inhibitor (slpi): associations with oropharyngeal cancer and treatment outcome.
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/ef3b1aeae8964c278ab48c2ed0cc7904
work_keys_str_mv	AT brittneyldickey oralsecretoryleukocyteproteaseinhibitorslpiassociationswithoropharyngealcancerandtreatmentoutcome AT bradleysirak oralsecretoryleukocyteproteaseinhibitorslpiassociationswithoropharyngealcancerandtreatmentoutcome AT lauramartingomez oralsecretoryleukocyteproteaseinhibitorslpiassociationswithoropharyngealcancerandtreatmentoutcome AT richardrreich oralsecretoryleukocyteproteaseinhibitorslpiassociationswithoropharyngealcancerandtreatmentoutcome AT marthaabrahamsen oralsecretoryleukocyteproteaseinhibitorslpiassociationswithoropharyngealcancerandtreatmentoutcome AT kimberlyisaacssoriano oralsecretoryleukocyteproteaseinhibitorslpiassociationswithoropharyngealcancerandtreatmentoutcome AT christinehchung oralsecretoryleukocyteproteaseinhibitorslpiassociationswithoropharyngealcancerandtreatmentoutcome AT annargiuliano oralsecretoryleukocyteproteaseinhibitorslpiassociationswithoropharyngealcancerandtreatmentoutcome
_version_	1718374558499602432

Oral secretory leukocyte protease inhibitor (SLPI): Associations with oropharyngeal cancer and treatment outcome.

Ejemplares similares